Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity

Vaccine

Volumn 30, Issue 48, 2012, Pages 6777-6782

  Gregory, A E ^a   Williamson, E D ^b   Prior, J L ^b   Butcher, W A ^b   Thompson, I J ^b   Shaw, A M ^a   Titball, R W ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Carbodiimide; Gold nanoparticle; Plague; Vaccine; Y. pestis

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL ANTIGEN; CHLORIDE; GOLD NANOPARTICLE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; N (3 DIMETHYLAMINOPROPYL) N' ETHYLCARBODIIMIDE HYDROCHLORIDE; N HYDROXYSUCCINIMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CONJUGATION; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MACACA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM; YERSINIA PESTIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; DRUG CARRIERS; FEMALE; GOLD; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; NANOPARTICLES; PLAGUE VACCINE;

EID: 84868202387     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.021     Document Type: Article

References (49)

1. Evans R.G., Crutcher J.M., Shadel B., Clements B., Bronze M.S. Terrorism from a public health perspective. Am J Med Sci 2002, 323(June (6)):291-298.
2. Perry R.D., Fetherston J.D. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 1997, 10:35-66.
3. Simpson W.J., Thomas R.E., Schwan T.G. Recombinant capsular antigen (fraction 1) from Yersinia pestis induces a protective antibody response in BALB/c mice. Am J Trop Med Hyg 1990, 43(October (4)):389-396.
4. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., Leary S.E., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 1995, 12(December (3-4)):223-230.
5. Andrews G.P., Heath D.G., Anderson G.W., Welkos S.L., Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 1996, 64(June (6)):2180-2187.
6. Williamson E.D., Flick-Smith H.C., LeButt C., Rowland C.A., Jones S.M., Waters E.L., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 2005, 73:3598-3608.
7. Fellows P., Adamovicz J., Hartings J., Sherwood R., Mega W., Brasel T., et al. Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). Vaccine 2010, 28(49):7748-7756.
8. Hart M.K., Saviolakis G.A., Welkos S.L., House R.V. Advanced development of the rF1V and rBV A/B vaccines: progress and challenges. Adv Prev Med 2012, 2012:14.
9. Fahmy T.M., Fong P.M., Park J., Constable T., Saltzman W.M. Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS J 2007, 9(2):E171-E180.
10. Bawarski W.E., Chidlowsky E., Bharali D.J., Mousa S.A. Emerging nanopharmaceuticals. Nanomedicine: NBM 2008, 4:273-282.
11. Chen S., Kimura K. Synthesis and characterization of carboxylate-modified gold nanoparticle powders dispersible in water. Langmuir 1999, 15:1075-1082.
12. Chen Y.S., Chen S.C., Kao C.M., Chen Y.L. Effects of soil pH, temperature and water content on the growth of Burkholderia pseudomallei. Folia Microbiol (Praha) 2003, 48(2):253-256.
13. Turkevich J., Stevenson P.C., Hillier J. A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc 1951, 11:55-75.
14. Chithrani B.D., Ghazani A.A., Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6(March (4)):662-668.
15. Taylor U., Klein S., Petersen S., Kues W., Barcikowski S., Rath D. Nonendosomal cellular uptake of ligand-free, positively charged gold nanoparticles. Cytometry A 2010, 77(May (5)):439-446.
16. Xia T., Rome L., Nel A. Nanobiology: particles slip cell security. Nat Mater 2008, 7(7):519-520.
17. Bhumkar D., Joshi H., Sastry M., Pokharkar V. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm Res 2007, 24(8):1415-1426.
18. Pan Y., Li Y.-j., Zhao H.-y., Zheng J.-m., Xu H., Wei G., et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002, 249(1-2):139-147.
19. Fuller D.H., Loudon P., Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006, 40(1):86-97.
20. Luo D., Saltzman W.M. Synthetic DNA delivery systems. Nat Biotech 2000, 18(1):33-37.
21. Miller J., Williamson E.D., Lakey J.H., Pearce M.J., Jones S.M., Titball R.W. Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol Med Microbiol 1998, 21(July (3)):213-221.
22. Williamson D.E., Sharp G.J.E., Eley S.M., Vesey P.M., Pepper T.C., Titball R.W., et al. Local and systemic immune response a microencapsulated sub-unit vaccine to for plague. Vaccine 1996, 14:1613-1619.
23. Brewer S.H., Glomm W.R., Johnson M.C., Knag M.K., Franzen S., Probing BSA Binding to citrate-coated gold nanoparticles and surfaces. Langmuir 2005, 21:9303-9307.
24. Williamson E.D., Packer P.J., Waters E.L., Simpson A.J., Dyer D., Hartings J., et al. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague. Vaccine 2011, 29(29-30):4771-4777.
25. Quenee L.E., Ciletti N.A., Elli D., Hermanas T.M., Schneewind O. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines. Vaccine 2011, 29(38):6572-6583.
26. Alonso M.J., Gupta R.K., Min C., Siber G.R., Langer R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994, 12(4):299-306.
27. Alonso M.J., Cohen S., Park T.G., Gupta R.K., Siber G.R., Langer R. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm Res 1993, 10(7).
28. O'Hagan D.T., Jeffery H., Roberts M.J.J., McGee J.P., Davis S.S. Controlled release microparticles for vaccine development. Vaccine 1991, 9(10):768-771.
29. Demento S.L., Cui W., Criscione J.M., Stern E., Tulipan J., Kaech S.M., et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 2012, 33(June (19)):4957-4964.
30. Musumeci T., Ventura C.A., Giannone I., Ruozi B., Montenegro L., Pignatello R., et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 2006, 325(1-2):172-179.
31. Mahapatro A., Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in vivo delivery of drugs and vaccines. J Nanobiotechnol 2011, 9:55.
32. Emeny R.T., Wheeler C.M., Jansen K.U., Hunt W.C., Fu T.M., Smith J.F., et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 2002, 76(August (15)):7832-7842.
33. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24(33-34):5937-5949.
34. Uto T., Akagi T., Hamasaki T., Akashi M., Baba M. Modulation of innate and adaptive immunity by biodegradable nanoparticles. Immunol Lett 2009, 125(June (1)):46-52.
35. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 2007, 178(March (5)):2979-2986.
36. Caputoa A., Castaldello A., Brocca-Cofanoa E., Voltana R., Bortolazzi F., Altavilla G., et al. Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. Vaccine 2009, 27:3605-3615.
37. Chen Y.S., Hung Y.C., Lin W.H., Huang G.S. Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 2010, 21(May (19)):195101.
38. Parween S., Gupta P.K., Chauhan V.S. Induction of humoral immune response against PfMSP-1(19) and PvMSP-1(19) using gold nanoparticles along with alum. Vaccine 2011, 29(March (13)):2451-2460.
39. Wang Y.-T., Lu X.-M., Zhu F., Huang P., Yu Y., Zeng L., et al. The use of a gold nanoparticle-based adjuvant to improve the therapeutic efficacy of hNgR-Fc protein immunization in spinal cord-injured rats. Biomaterials 2011, 32(31):7988-7998.
40. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 1997, 15(July (10)):1079-1084.
41. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 1999, 116(April (1)):107-114.
42. Williamson E.D., Flick-Smith H.C., Waters E., Miller J., Hodgson I., Le Butt C.S., et al. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates. Microb Pathog 2007, 42(1):11-21.
43. Abdelhalim M.A.K., Mady M.M. Liver uptake of gold nanoparticles after intraperitoneal administration in vivo: a fluorescence study. Lipids Health Dis 2011, 10(October):9.
44. Yamamoto A., Honma R., Sumita M., Hanawa T. Cytotoxicity evaluation of ceramic particles of different sizes and shapes. J Biomed Mater Res, Part A 2003, 68A(2):244-256.
45. Connor E.E., Mwamuka J., Gole A., Murphy C.J., Wyatt M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005, 1:325-327.
46. Lasagna-Reeves C., Gonzalez-Romero D., Barria M.A., Olmedo I., Clos A., Sadagopa Ramanujam V.M., et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun 2010, 393(March (4)):649-655.
47. Lovric J., Cho S.J., Winnik F.M., Maysinger D. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem Biol 2005, 12(11):1227-1234.
48. 2 on zebrafish larvae and a liver cell-line. Aquat Toxicol 2011, 105(October (3-4)):344-354.
49. Titball R.W., Howells A.M., Oyston P.C., Williamson E.D. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect Immun 1997, 65(May (5)):1926-1930.